“It all started with a particular drug, Cyclosporine A, which is an immunosuppressant,” Hawkshaw explains. “It’s typically given to transplant patients to stop them rejecting new organs post-surgery and it’s been observed that it enhances hair growth. But the thing is, you don’t really want to give this to patients normally because you don’t want to suppress their immune system. So, I used that drug to treat human hair follicles in the lab to try and identify how it actually worked.”
“Curis (now-dormant company) had performed a lot of studies on targeting the Hedgehog pathway for hair growth with very promising results, however, their compounds caused orthosteric activation of the pathway (turning it on everywhere and robustly which is not safe) vs. Oxy133 which causes a much more regulated and limited allosteric activation of the pathway only in stem cells. This could make Oxy133 a blockbuster. Let’s see what happens.” 
Certainly a company with a unique background and game plan, HairClone has received some recent media attention. The UK biotech startup was featured in this month’s publication of “Consulting Room” online magazine. In the article both Dr. Bessam Farjo and Paul Kemp of HairClone provided insight as to the company’s current progress and plans for the future. Things seem to be coming along well for HairClone and we should expect to hear from them again within the next several weeks. Full story is on Articles main page.

Key features: Dr. Zeichner recommends the Keratin Oil Shampoo and Conditioner by OGX for thinning or fine hair that needs the extra strength. This budget-friendly option uses keratin proteins mixed with argan oil to nourish, condition, and strengthen strands, and it's only $16 for the set. The smoothing formula can also increase elasticity for less breakage and split ends.

×